5395232025-01-012025-03-315395232025-03-315395232024-03-315395232024-04-012025-03-315395232025-01-012025-03-31in-capmkt:OtherExpenses1Member5395232024-04-012025-03-31in-capmkt:OtherExpenses1Member5395232025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15395232024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15395232025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares539523ALKEMNOTLISTEDINE540L01014ALKEM LABORATORIES LIMITEDMain BoardEquity2024-04-012025-03-312025-05-292025-05-16INRMillionsQuarterlyFourth quarterSingle segmentThe Company is exclusively engaged in pharmaceutical business2025-05-2911:25:002025-05-2913:45:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31UnauditedConsolidated3143750000014596000003289710000077703000003799600000122290000061635000002842000001124900000856830000028933700000396340000003963400000842500000-10920000073330000003230100000000-62000003223900000-25900000319800000030586000001653000003032800000165200000239100000225.5725.570025.5725.572024-04-012025-03-31AuditedConsolidated12964520000049374000001345826000003440370000015140200000-1901300000245392000001217000000357160000032341900000109312300000252703000000252703000005236000000-21257000003110300000022160000000000-6200000221538000001972000002235100000021654800000499000000218623000004887000002391000002119609600000181.11181.1100181.11181.11Other Expenses8568300000Other Expenses323419000002063930000047655000000423110000036527000007152000000094324000000047536000001418600000017382500000188050000067452800000292241000009022600000246625000003041400000125894000009040000021154800000705611000008326700000108111900000134630000001769110000002391000001196096000001198487000004487600000124336300000310910000000062141000009323200000338220000000219500000129249000007518800000879800000175137000001839350000084155000003432780000030570000001591100000611000000039586900000629000000525747000001769110000001. The above consolidated financial results are prepared in accordance with the lndian Accounting Standards prescribed under section 133 of the Companies Act 2013 and are in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI LODR Regulations 2015. The Consolidated Financial results are prepared in accordance with Ind AS 110 Consolidated Financial Statements. <BR> <BR> 2. The above consolidated financial results of the Group were reviewed and recommended by the Audit Committee on 28 May 2025 and subsequently approved by the Board of Directors at its meeting held on 29 May 2025. The auditors have expressed an unmodified opinion on the financial results for the year ended 31 March 2025. <BR> <BR> The figures for the quarter ended 31 March 2025 and 31 March 2024 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevent financial year. <BR> <BR> 3. The Board of Directors of the Parent Company at their meeting held on 10 December 2024 have approved the transfer of its Generic Business Undertaking to Alkem Wellness Limited a wholly owned subsidiary of the Parent Company as a going concern on a slump sale basis. The Parent Company is currently in the process of executing Business Transfer Agreement. Since the carve out of the Generic Business Undertaking is to a wholly owned subsidiary of the Parent Company there is no impact on the consolidated financial results. <BR> <BR> 4. The comparative financial information of the Group for the quarter and year ended 31 March 2024 prepared in accordance with Ind AS included in this statement have been reviewed and audited respectively by the predecessor auditor. The report of the predecessor auditor on the comparative financial information is dated 29 May 2024. <BR> <BR> 5. Exceptional items for the year ended 31 March 2024 includes <BR> a. Impairment loss of INR 576.6 Million in respect of one of the manufacturing units located at St. Louis under S and B Pharma LLC USA a step-down subsidiary of the Parent Company owing to impairment indicators. <BR> b. Net loss on account of a cyber security incident at one of the subsidiaries amounting to INR 222.7 Million. <BR> c. Impairment loss of INR 415.6 Million towards its plant located at Indore. <BR> <BR> Exceptional items for the quarter ended 31 March 2024 includes recovery of loss on cyber security incident amounting to INR 290.4 Million and impairment loss of INR 415.6 Million towards its plant located at Indore. <BR> <BR> 6. During the year the Group as a part of its ongoing initiative of networking strategy and optimization of manufacturing facilities has identified divestment of its Indore facility. Consequently related assets and liabilities are disclosed as held for sale. These assets and liabilities have been carried at cost as the same are lower than the fair value expected out of sale. <BR> <BR> 7. The Board of Directors at its meeting held on 29 May 2025 have declared a final dividend of INR 8 per equity share face value of INR 2 each in addition to the interim dividend INR 37 per equity share face value of INR 2 each declared on 07 February 2025. The final dividend is subject to approval at the ensuing annual general meeting of the Company. <BR> <BR> 8. The Group operates in one reportable business segment i.e. Pharmaceuticals accordingly no separate disclosure of segment information has been made.1217000000-2612300000-218550000002499000000000216650000000035716000000241700000000111600000170000035878000000-4187000000014600000000-110170000024168600000000504020000001912840000000000000408400000675620000000000000000471506000005726920000000001700000347710000000-129876000000000000028790000004820100000316500000504620000080610000000-8109900000-1969100000105100000-1864000000663100000-1200900000Remeasurements of defined benefit plans-64300000-64300000Remeasurements of defined benefit plans-218100000-218100000-21700000-72100000Foreign currency translation difference of foreign operations1670000016700000Foreign currency translation difference of foreign operations34320000034320000000-25900000197200000AuditedtrueDeloitte Haskins and Sells LLPtrue2027-07-31